West Virginia Cannabis: $7.14/g Flower, ~15% Legal Capture, and 64 Dispensaries Competing for 35,000 Patients

West Virginia has 64 operational dispensaries, 9 growers, and a medical cannabis program that generated an estimated $93 million in 2025 — all serving approximately 35,000 registered patients in the poorest state in the country. Prices have fallen 15.4% in two years as indoor-only producers compete for a patient base that has stopped growing. The ~15% legal capture rate isn't primarily a density problem — West Virginia has more dispensaries per patient than almost any other medical market in the dataset. It's an affordability and access problem, compounded by mandatory indoor growing costs and card requirements that leave an estimated 207,000 cannabis consumers outside the legal system entirely.

Market Overview

West Virginia's Medical Cannabis Act (SB 386) was signed by Governor Jim Justice on April 19, 2017, making West Virginia the 29th state to pass a medical cannabis law. The program was slow to launch: dispensary permits were announced January 29, 2021, public patient registration opened May 3, 2021, and the first dispensary opened November 12, 2021 in Morgantown. The program is administered by the Office of Medical Cannabis (OMC) under the Bureau for Public Health.

Key metrics:

• 64 operational dispensaries (per OMC as of September 2025; 93 total active commercial licenses including growers and processors, per NCS Analytics)
• $7.14/g flower price (October 2025, per OMC 2025 Biennial Report); down from $8.43/g in October 2023 — a 15.4% decline
• ~$93M estimated 2025 annual sales (NCS Analytics; $94M in 2024)
• 10% excise tax on dispensary gross receipts; no separate consumer sales tax
• ~15% estimated legal market capture (dollars)
• ~35,200 active patient cardholders (late 2025); patient growth has plateaued
• Medical-only — multiple adult-use legalization bills have been introduced but none has become law; simple possession remains criminal, though first-offense possession of less than 15 grams is routed to conditional discharge under §60A-4-407
• No outdoor cultivation permitted — all production must be indoor
• 15 qualifying serious medical conditions including chronic pain, PTSD, cancer, epilepsy, and multiple sclerosis

Flower Pricing

The OMC's 2025 Biennial Report provides monthly flower prices from November 2023 through October 2025, drawn from Metrc seed-to-sale data. The trend is unambiguous: prices peaked at $8.03/g in July 2024 and declined steadily to $6.97/g in August 2025 before a slight recovery to $7.14/g in October 2025. From October 2023 to October 2025, prices fell 15.4%.

The driver is structural. West Virginia mandates indoor-only cultivation — 9 licensed growers operating greenhouse or warehouse facilities with higher overhead than outdoor or greenhouse operations in permissive states. As those 9 growers compete for the same 35,000 patients across 64 dispensaries, price compression is the predictable result. The trend line points toward continued decline.

At $7.14/g final consumer price, West Virginia is among the more affordable medical markets in the dataset — cheaper than Pennsylvania, Maryland, Arkansas, and Vermont. The indoor-only mandate that drives costs up is simultaneously driving competition that brings them down.

Tax Structure

• 10% excise tax on gross receipts paid by dispensaries at point of sale
• No consumer-facing state sales tax on medical cannabis
• Excise is embedded in retail price — consumers see $7.14/g, not $6.49/g + tax
• ~$38 million in tax revenue accumulated since program launch in 2021
• Tax revenue is currently unspendable: the state treasurer's office cannot deposit the funds through federally regulated banks due to cannabis's Schedule I status. The money sits in a holding account.

The banking impasse is a policy-level absurdity. West Virginia has collected tens of millions in legitimate state tax revenue that cannot be moved through the normal state financial infrastructure because the federal government still classifies the product as having "no accepted medical use."

Total Addressable Market

West Virginia's adult population 21+ is approximately 1.356 million (U.S. Census Bureau 2024 single-year age estimates). Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:

• 1,356,000 adults 21+
• 244,000 estimated regular consumers (18%)
• TAM at $7.14/g: ~$636M annually

Against ~$93M in 2025 estimated sales:

West Virginia's estimated legal market capture rate: ~15%.

The patient spending figures confirm the program serves its cardholders intensively. $93M divided by 35,200 active patients equals approximately $220/month per active cardholder — nearly identical to Arkansas ($210/month) and Vermont ($197/month in a fully open adult-use market). The ~85% gap represents roughly 207,000 estimated consumers with no legal pathway.

Revenue Trend

The 37% growth in 2024 was driven by rapid patient card expansion (27,496 in 2023 to 34,371 in 2024). That patient growth has since plateaued at approximately 35,000 — and monthly revenues have flattened accordingly. This is the structural ceiling of a card-gated medical program: once the addressable patient population stabilizes, so does revenue.

Dispensary Density

West Virginia has 64 operational dispensaries serving approximately 35,200 registered patients — roughly 182 dispensaries per 100,000 patients, or one dispensary for every 550 cardholders. Against the total adult population of 1.356 million, density is 4.7 per 100,000 adults — low by adult-use market standards but within the range of medical-only markets.

Revenue per dispensary: $93M ÷ 64 = $1.45M/store annually — among the lowest in the dataset. For context, Arkansas generates $8.09M per store with 36 dispensaries. The mismatch between store count and market size in West Virginia is extreme: 64 dispensaries chasing 35,000 patients produces a market where many operators are running at thin or negative margins, which is itself accelerating price compression as stores compete for the same limited patient pool.

West Virginia originally issued 100 dispensary permits. By September 2025, 64 were operational — the rest had either not progressed or been terminated by the OMC.

Home Cultivation

Home cultivation is not permitted under West Virginia's Medical Cannabis Act. As with other medical-only markets, the home grow economics argument applies regardless: at $7.14/g and declining, indoor cultivation economics don't favor personal grows. The absence of home cultivation in WV doesn't meaningfully change the market picture.

What the CHS Literature Missed

West Virginia's Medicaid drug review contractor, Acentra (operating as Kepro), published a 2024 Q3 clinical newsletter summarizing the American Gastroenterological Association's updated CHS guidance. The newsletter contains an unusual internal contradiction worth examining.

In the same paragraph, it states: "the overall prevalence of CHS is 0.1%" — and then immediately notes that "some studies estimate that up to 33% of marijuana smokers have experienced CHS at some point."

Both numbers appear in the same sentence. The document does not reconcile them.

The AGA's own diagnostic criteria cited in the same newsletter require: cannabis use for at least one year prior to symptom onset; use more than four times per week; vomiting episodes at least three times annually; and symptom resolution after at least six months of abstinence. These are not incidental conditions. The AGA is describing a specific clinical syndrome affecting a narrow subset of heavy, long-term daily users — and the contractor's own newsletter puts the population-level prevalence at 0.1%.

West Virginia has approximately 35,200 registered patients. If CHS affected the program at the 33% rate some studies suggest, roughly 11,600 West Virginia cardholders would be active sufferers — generating a clinical signal that the OMC's 2025 Biennial Report, the state's own surveillance document, would be expected to capture. The report covers adverse events, benefits and risks to patients, and programmatic outcomes in detail. CHS does not appear in it.

The 0.1% figure is consistent with what population-level consumption analysis shows about actual CHS frequency. The 33% figure comes from a narrow sample of chronic, daily users presenting at an urban emergency department — a population selected specifically for heavy use and acute symptoms, not a representative slice of the cannabis-consuming public or West Virginia's medical patients.

The Bottom Line

West Virginia's medical cannabis program is doing what over-built medical markets do: prices are compressing as too many dispensaries compete for a patient base that has stopped growing. The $7.14/g retail price — down 15.4% in two years — is the market finding equilibrium in a constrained system. The ~15% capture rate reflects a card requirement that limits legal access to 35,000 patients out of an estimated 244,000 consumers, compounded by income constraints in the country's poorest state.

The structural barriers are layered in ways unique to West Virginia. No outdoor growing keeps production costs elevated. Simple possession remains a criminal offense — and while first-offense possession of less than 15 grams routes to conditional discharge rather than incarceration, the criminal framework makes the informal market the only practical option for the roughly 207,000 estimated consumers without cards. And $38 million in legitimately collected tax revenue sits in a holding account because federal law won't let the state spend it.

The program has reached its natural ceiling as a medical-only system. Patient growth is flat. Revenue growth is flat. Prices are falling. The next variable that would change any of those numbers is adult-use legalization — and West Virginia's legislature has shown no appetite for it.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.